TY - JOUR
T1 - Choroidal neovascularization with interferon associated retinopathy
T2 - Case report and review of literature
AU - Bazarah, Salem M.
AU - Ritenour, Rusty
AU - Patel, Sunil T.
AU - Hirsch, Geri
AU - Peltekian, Kevork M.
AU - Cruess, Alan F.
PY - 2006
Y1 - 2006
N2 - We report a case of new interferon-associated ocular complication during treatment with combination of pegylated interferon plus ribavirin for chronic hepatitis C infection. Our patient developed choroidal neovascularization in addition to the classic interferon associated retinopathy. Choroidal neovascularization has not been reported before in association with interferon induced retinopathy. We describe our management to control the ocular symptoms and the retinal lesions with one year follow up. We also provide literature report on the natural history, the pathophysiology and the variable characteristics of interferon associated retinopathy versus hepatitis C related ophthalmopathy.
AB - We report a case of new interferon-associated ocular complication during treatment with combination of pegylated interferon plus ribavirin for chronic hepatitis C infection. Our patient developed choroidal neovascularization in addition to the classic interferon associated retinopathy. Choroidal neovascularization has not been reported before in association with interferon induced retinopathy. We describe our management to control the ocular symptoms and the retinal lesions with one year follow up. We also provide literature report on the natural history, the pathophysiology and the variable characteristics of interferon associated retinopathy versus hepatitis C related ophthalmopathy.
UR - http://www.scopus.com/inward/record.url?scp=33748934952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748934952&partnerID=8YFLogxK
U2 - 10.1016/s1665-2681(19)32004-6
DO - 10.1016/s1665-2681(19)32004-6
M3 - Article
C2 - 17060876
AN - SCOPUS:33748934952
SN - 1665-2681
VL - 5
SP - 172
EP - 176
JO - Annals of Hepatology
JF - Annals of Hepatology
IS - 3
ER -